Robuta

https://www.biopharmadive.com/news/jj-predicts-faster-coronavirus-vaccine-sales-amid-debate-over-boosters/603705/ J&J predicts faster coronavirus vaccine sales amid debate over boosters | BioPharma Dive The pharmaceutical company expects $2.5 billion in sales from its shot this year, despite concerns over protection against variants and significant... coronavirus vaccine https://www.biopharmadive.com/news/sanofi-vaccine-sales-fourth-quarter-2025-earnings/810829/ Sanofi expects vaccine sales growth to dip amid ‘challenging environment’ | BioPharma Dive On a conference call, executives cited “confusion” and declining vaccination rates in the U.S. while discussing a quarterly sales decline and anticipated... vaccine salesto dip https://health.economictimes.indiatimes.com/news/pharma/astrazeneca-profits-fall-covid-vaccine-sales-slide/93237642 AstraZeneca profits fall, Covid vaccine sales slide, ETHealthworld Covid Vaccine: Net profit slumped 64 percent to $746 million compared with the first six months of last year, AstraZeneca said in a statement. Operating... covid vaccineastrazenecaprofitsfallsales https://www.insiderfinance.io/news/moderna-q1-2026-results-show-vaccine-sales-lift Moderna Q1 2026 Results Show Vaccine Sales Lift | InsiderFinance Moderna Q1 2026 results showed COVID vaccine sales lifted revenue while a $0.9 billion litigation settlement widened GAAP loss and may shift positioning. results showvaccine salesmodernalift